Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabosun II: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
NCT03541902Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabozantinib in renal cell carcinoma (RCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival up to 2 years. Started May 2018; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03541902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541902.